Trailing 12 months EPS jumped from $.25 from $.15then new product put in the mix and SP drops from the $10-$11 level to $7 level. Hefty multiple - absolutely. Deserved - absolutely. Behind the scenes - excellent cashflow, no debt, unused line of credit, new product ready for EXISTING sales force to carry in their bag to EXISTING doctors, growing quarter over quarter revenues and EPS, low float......... Another example of couple hundred daily share trades bringing stock price down. Look forward to update on recently added product integration....... Hopefully summer season goldrums are over and investors/traders concentrate on all these EARNINGS making companies with REAL growth. So frustrating to see EBITDA based companies with loss EPS skyrocket while companies like RX plummet!!!!!